Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.


Date Title Topic
25 Jul 2018 NICE Recommends Pembrolizumab for Untreated PD-L1-positive Metastatic NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
24 Jul 2018 Molecular Characterisation of Clinical Responses to Anti-PD-1 Therapy in Metastatic Gastric Cancer Gastrointestinal cancers - Translational research - Cancer Immunology and Immunotherapy
23 Jul 2018 FDA Approves Ivosidenib for Relapsed or Refractory Acute Myeloid Leukaemia Haematologic malignancies - Personalised medicine - Anticancer agents & Biologic therapy
20 Jul 2018 FDA Expands Ribociclib Indication in HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
19 Jul 2018 EMA PRAC Recommends Restricting Use of Prostate Cancer Medicine Radium-223 Dichloride Genitourinary cancers - Anticancer agents & Biologic therapy
18 Jul 2018 ESMO Releases New Patient Guide in Breast Cancer Breast cancer
18 Jul 2018 FDA Broadens Approval for Enzalutamide to Include Non-Metastatic Castration-Resistant Prostate Cancer Genitourinary cancers - Anticancer agents & Biologic therapy
17 Jul 2018 NICE Issues Guideline for Primary Brain Tumours and Brain Metastases in Adults Central nervous system malignancies
16 Jul 2018 A Comprehensive Catalogue of Stromal Cells in Human Lung Tumours at Single-Cell Resolution Lung and other thoracic tumours - Translational research
13 Jul 2018 FDA Grants Accelerated Approval to Ipilimumab in Combination with Nivolumab for MSI-H or dMMR mCRC Gastrointestinal cancers - Cancer Immunology and Immunotherapy
12 Jul 2018 EMA Recommends Granting a Marketing Authorisation for Liposomal Formulation of a Fixed Combination of Daunorubicin and Cytarabine Haematologic malignancies - Anticancer agents & Biologic therapy
11 Jul 2018 FDA Approves the Ventana PD-L1 (SP142) Assay for PD L1 Expression in ≥ 5% IC in Urothelial Carcinoma Tissue Genitourinary cancers - Personalised medicine - Cancer Immunology and Immunotherapy
10 Jul 2018 Study Identifies Factors Associated with Diffuse Intrinsic Pontine Glioma that Indicate Better Survival Central nervous system malignancies
09 Jul 2018 EMA Recommends Granting Marketing Authorisations for the First Two CAR T-cell Therapies in the EU Haematologic malignancies - Cancer Immunology and Immunotherapy
06 Jul 2018 Immune Driver of Castration-Resistant Prostate Cancer Identified Genitourinary cancers - Basic science - Translational research